missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Phospho-Bcr (Tyr177) Polyclonal Antibody

Description
Antibody detects endogenous levels of Bcr only when phosphorylated at Tyrosine 177.
A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. The protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac. Two transcript variants encoding different isoforms have been found for this gene.
Specifications
Specifications
| Antigen | Phospho-Bcr (Tyr177) |
| Applications | Western Blot, Immunocytochemistry |
| Classification | Polyclonal |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 |
| Gene | Bcr |
| Gene Accession No. | P11274, Q6PAJ1 |
| Gene Alias | 5133400C09Rik; ABL; AI561783; AI853148; ALL; BCR; BCR activator of RhoGEF and GTPase; BCR protein; BCR, RhoGEF and GTPase activating protein; bcr/abl; BCR/FGFR1 chimera protein; BCR1; breakpoint cluster region; breakpoint cluster region homolog; breakpoint cluster region protein; c-ABL; c-abl oncogene 1; CML; D22S11; D22S662; EC 2.7.11.1; FGFR1/BCR chimera protein; JTK7; Kiaa3017; mKIAA3017; p150; PHL; renal carcinoma antigen NY-REN-26; RP11-83J21.1; v-abl |
| Gene Symbols | Bcr |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?